SPINK7/ECRG2 (SPINK7)
(Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))
Épitope
C-Term
Reactivité
Humain, Souris, Rat
Hôte
Poulet
Clonalité
Polyclonal
Conjugué
Cet anticorp SPINK7/ECRG2 est non-conjugé
Application
ELISA, Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Specificité
ECRG2 antibody is predicted to not cross-react with other ECRG family members
Purification
ECRG2 Antibody is affinity chromatography purified via peptide column.
Immunogène
ECRG2 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of human ECRG2. The immunogen is located within the last 50 amino acids of ECRG2.
SPINK7
Reactivité: Humain, Souris
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
Cy5
Indications d'application
ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL.
Antibody validated: Western Blot in mouse samples and Immunohistochemistry in rat samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
ECRG2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
ECRG2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
SPINK7/ECRG2 (SPINK7)
(Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))
ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.